Orthofix also reported full year sales at $579 million. Robert Vaters, president and CEO of Orthofix, said 2011 was a transition year for the company and it is now poised for long term revenue growth across the regenerative and repair products platforms.
The company’s spine products were flat during the fourth quarter at $78.6 million, but the orthopedics products grew by 16 percent to $44.5 million. The sports medicine business grew by 10 percent to $27.5 million. The increases were led by external fixation products and international markets.
Related Articles on Orthopedic Devices:
Small Bone Innovations Names Michael Simpson President & CEO
Global Orthopedic Device Market to Reach $61.3B by 2017
ArthroCare Revenues Down in 2011
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.